Trial Profile
A study to investigate VT-1129 for the treatment of cryptococcal meningitis
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Jun 2016
Price :
$35
*
At a glance
- Drugs Quilseconazole (Primary)
- Indications Cryptococcal meningitis
- Focus Adverse reactions
- 01 Jun 2016 According to a Viamet Pharmaceuticals media release, the US FDA has granted Fast Track Designation for VT-1129 for the treatment of cryptococcal meningitis. It has also granted Orphan Drug Designation and Qualified Infectious Disease Product designation to VT-1129.
- 01 Jun 2016 According to a Viamet Pharmaceuticals media release, status changed from planning to recruiting.
- 19 Sep 2015 According to a Viamet Pharmaceuticals media release, the company expect to initiate this trial in the fourth quarter of 2015.